CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Cardiovascular Outcomes with Sodium-glucose Co-transporter 2 Inhibitors: A review of the Clinical Evidence

Last updated: November 5, 2015
Project Number: RC0719-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the clinical evidence regarding cardiovascular outcomes with the use of SGLT-2 inhibitors for patients with type-2 diabetes?

Key Message

Sodium glucose co-transport (SGLT-2) inhibitors significantly reduced systolic and diastolic blood pressure in patients with type-2 diabetes mellitus (T2DM) compared with placebo or active controls (glimepiride, glipizide, and sitagliptin). A post hoc analysis of data from five randomized controlled trials showed that empagliflozin significantly reduced risk factors of arterial stiffness such as double product, mean arterial pressure, and pulse pressure compared with placebo. Empagliflozin demonstrated a significantly lower risk of death from cardiovascular causes, and death from any cause compared with placebo in T2DM patients at high risk for cardiovascular events receiving standard care.  However, a systematic review and meta-analysis found that the overall odds of cardiovascular events among T2DM patients were not significantly lower with SGLT-2 inhibitors compared with placebo and active controls (glimepiride, glipizide, and sitagliptin).